Advanced enzyme tech has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate submission demonstrates the company's adherence to mandatory regulatory requirements governing securities dematerialisation processes.

Regulatory Compliance Details

The certificate was submitted under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Company Secretary and Head-Legal Sanjay Basantani signed the submission letter dated April 10, 2026, forwarding the certificate to both BSE Limited and National Stock Exchange of India Limited.

Registrar and Transfer Agent Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar and Transfer Agents. The agency provided the confirmation certificate dated April 3, 2026, signed by Sr. Vice President-Corporate Registry Ashok Shetty.

The certificate confirms that securities received from depository participants for dematerialisation during the quarter were properly processed within prescribed timelines. MUFG Intime confirmed that all security certificates received for dematerialisation were appropriately verified, mutilated, and cancelled after due verification by depository participants.

Dematerialisation Process Compliance

The confirmation certificate validates several key compliance aspects:

• Securities received for dematerialisation were confirmed or rejected to depositories within required timeframes
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates were properly mutilated and cancelled after verification
• Depository names were substituted in the register of members as registered owners

This quarterly filing represents standard regulatory compliance for listed companies, ensuring proper handling of securities dematerialisation processes and maintaining transparency in depository participant operations.

Advanced enzyme tech has announced a senior management change with the resignation of Mr. Dipak Roda from his position as Senior Vice President - Marketing and Business Development. The resignation becomes effective from the close of business hours on April 09, 2026.

Regulatory Disclosure

The company informed stock exchanges about this development on March 11, 2026, in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made pursuant to SEBI Master Circular dated November 11, 2024, ensuring compliance with regulatory requirements for senior management personnel changes.

Resignation Details

In his resignation letter dated March 10, 2026, Roda stated his intention to "pursue new challenges and opportunities outside the Company." He expressed gratitude for the experience and learning opportunities gained during his tenure, acknowledging the meaningful contributions he was able to make to various projects.

Subsidiary Impact

Roda's resignation extends beyond Advanced Enzyme Technologies Limited, as he also stepped down from his position as Non-Executive Director of the company's subsidiary, Advanced Enzytech Solutions Limited. This dual resignation ensures a complete transition from his roles within the corporate group.

Professional Acknowledgment

The departing executive expressed appreciation for the trust and opportunities provided during his tenure with the organization. His resignation letter highlighted the invaluable experience gained and the meaningful nature of his project involvement and contributions to the company's operations.

Corporate Communication

The company has uploaded the resignation intimation on its official website at www.advancedenzymes.com , ensuring transparency and accessibility of information for stakeholders. The disclosure includes the complete resignation letter along with stated reasons for departure, maintaining full regulatory compliance.